Effect of the two new calcium channel blockers mebudipine and dibudipine on vascular flow of isolated kidney of normal and diabetic rats

Pathophysiology

Volumn 18, Issue 3, 2011, Pages 175-184

  Sepehr Ara, Lili ^a   Mohajeri, Seyed Ahmad ^b   Mahmoudian, Massoud ^c  

^a ISLAMIC AZAD UNIVERSITY   (Iran)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Diabetic rats; Dibudipine; Isolated kidney; Mebudipine

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; DIBUDIPINE; DIHYDROPYRIDINE DERIVATIVE; MEBUDIPINE; NIFEDIPINE; PHENYLEPHRINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATTENUATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFICACY; DRUG POTENCY; ISOLATED KIDNEY; KIDNEY BLOOD FLOW; KIDNEY PERFUSION; MALE; NONHUMAN; PERFUSION PRESSURE; PRIORITY JOURNAL; RAT; STREPTOZOCIN DIABETES;

EID: 79954570397     PISSN: 09284680     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pathophys.2010.09.001     Document Type: Article

References (26)

1. Armenia A., Munavvar A.S., Abdullah N.A., Helmi A., Johns E.J. The contribution of adrenoceptor subtype(s) in the renal vasculature of diabetic spontaneously hypertensive rats. Br. J. Pharmacol. 2004, 142:719-726.
2. Fleckenstien A. Specific pharmacology of calcium in myocardium, cardiac pacemakers, and vascular smooth muscle. Annu. Rev. Pharmacol. Toxicol. 1977, 17:149-166.
3. Rouzrokh A., Ebrahimi S.A., Rahbar-roshandel N., Mahmoudian M. Effect of mebudipine and dibudipine, two new calcium channel blockers on voltage-activated calcium currents of PC12 cells. Acta Physiol. Hung. 2007, 94:199-207.
4. Jackson C.V., Carrier G.O. Supersensitivity of isolated mesenteric arteries to noradrenaline in the long-term experimental diabetic rat. J. Auton. Pharmacol. 1981, 1:399-405.
5. Wu D., Katz A., Lee C.H., Simon M.I. Activation of phospholipase C by α1-adrenergic receptors is mediated by the subunits of Gq family. J. Biol. Chem. 1992, 267:25798-25802.
6. Reams G.P. Do calcium channel blockers have renal protective effects?. Drugs Aging 1994, 4:263-287.
7. Mirkhani H., Omrani G.R., Ghiaee S., Mahmoudian M. Effect of mebudipine and dibudipine, two new calcium channel blockers, on rat left atrium, rat blood pressure and human internal mammary artery. J. Pharm. Pharmacol. 1999, 51:617-622.
8. Mirkhani H., Dirin M., Youssef-zayeh I. Machanism of vasoselective action of mebudipine, a new calcium channel blocker. Vasc. Pharm. 2005, 42:23-29.
9. Parving H.H., Tarnow L., Rossing P. Renal protection in diabetes: an emerging role for calcium antagonists. J. Cardiol. 1997, 88:56-62.
10. Muramatsu I., Suzuki F., Tanaka T., Yamamoto H., Morishima S. Alpha1-adrenoceptor subtypes and alpha1-adrenoceptor antagonists. Yakugaku Zasshi 2006, 126:187-198.
11. Zhang J., Berra-Romani R., Sinnegger-Brauns M.J., Striessnig J., Blaustein M.P., Matteson D.R. Role of Cav1.2 L-type Ca2+ channels in vascular tone: effects of nifedipine and Mg2+. Am. J. Physiol. Heart Circ. Physiol. 2007, 292:H415-H425.
12. Garcia-Sainz J.A., Villalobos-Molina R. The elusive α1-adrenoceptor: molecular and cellular characteristics and integrative roles. Eur. J. Pharmacol. 2004, 500:113-120.
13. Hayashi K., Kumagai H., Saruta T. Effects of efonidipine and ACE inhibitors on proteinuria in human hypertension with renal impairment. Am. J. Hypertens. 2003, 16:116-122.
14. Kam K.L., Hendriks M.G., Pijl A.J., Van Marle J., Van Veen H.A., Pfaffenorf M., Van Zwieten P.A. Contractile responses to various stimuli in isolated resistance vessels from simultaneously hypertensive and streptozotocin-diabetic rats. J. Cardiovasc. Pharmacol. 1996, 27:167-175.
15. Sepehr-Ara L., Babapoor V., Oryan S., Mahmoudian M. Effect of the two new calcium channel blockers mebudipine and dibudipine in comparison to nifedipine on vascular flow of isolated rat kidney. Sci. Pharm. 2009, 77:805-815.
16. Opie L.H., Yusuf S., Kubler W. Current status of safety and efficacy of calcium channel blockers in cardiovascular disease: a critical analysis based on 100 studies. Prog. Cardiovasc. Dis. 2000, 43:171-196.
17. Faizi M., Janahmadi H., Mahmoudian M. The effect of mebudipine and dibudipine, two new Ca2+ channel blockers, in comparison with nifedipine on Ca2+ spikes of F1 neuronal soma membrane in Helix aspersa. Acta Physiol. Hung. 2003, 90:243-254.
18. Mahmoudian M., Mirkhani H., Nehardani Z., Ghiaii S. Synthesis and biological activity of two new calcium channel blocker, mebudipine and dibudipine. J. Pharm. Pharmacol. 1997, 49:1229-1233.
19. Mahmoudian M. Mebudipine and dibudipine: a review. Iranian J. Pharm. Ther. 2003, 2:25-29.
20. Salomonsson M., Brannstrom K., Arendshorst W.J. α1-Adrenoceptor subtypes in rat renal resistance vessels: in vivo and in vitro studies. Am. J. Physiol. 2000, 278:F138-F147.
21. Khan M.H., Sattar M., Abdullah N.A., Johns E.J. Influence of combined hypertension and renal failure on functional α1-adrenoceptor subtypes in the rat kidney. Br. J. Pharmacol. 2008, 153:1232-1241.
22. Fedirko N.V., Kruglikov I.A., Kopach O.V., Vats J.A., Kostyuk P.G., Voitenko N.V. Changes in functioning of rat submandibular salivary gland under streptozotocin-induced diabetes are associated with alterations of Ca2+ signaling and Ca2+ transporting pumps. Biochim. Biophys. Acta 2006, 1762:294-303.
23. Beenen O.H., Mathy M.J., Pfaffendorf M., Van Zwieten P.A. Vascular responsiveness in isolated perfused kidneys of diabetic hypertensive rats. J. Hypertens. 1996, 14:1125-1130.
24. Wang R., Liu Y., Sauve R., Anand-Srivastava M.B. Diabetes-related abnormal calcium mobilization in smooth muscle cells are induced by hyperosmolality. Mol. Cell. Biochem. 1998, 183:79-85.
25. Wang R., Wu Y., Tang G., Wu L., Hanna S. Altered L-type Ca2+ channel currents in vascular smooth muscle cells from experimental diabetic rats. Am. J. Physiol. Heart Circ. Physiol. 2000, 278:H714-H722.
26. Bohlooli S., Mahmoudian M., Skellern G.G., Grant M.H., Tetty J.N.A. Metabolism of the dihydropyridine calcium channel blockers mebudipine and dibudipine by isolated rat hepatocytes. J. Pharm. Pharmacol. 2004, 56:1469-1475.